Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be SignificantJuan Berenguer, Inmaculada Jarrín, Leire Pérez‐Latorre et al.|Open Forum Infectious Diseases|2018Cited by 28
HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018Leire Pérez‐Latorre, Juan Berenguer, Rafael Micán et al.|Eurosurveillance|2021Cited by 19
Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002–2023)Juan Berenguer, Juan González‐García, Chiara Fanciulli et al.|Clinical Infectious Diseases|2025Cited by 5
Hodgkin and non‐Hodgkin lymphomas in the post‐antiretroviral therapy era according to <scp>HIV</scp> virological suppressionTeresa Aldámiz‐Echevarria, CoRIS Cohort, Francisco Tejerina et al.|HIV Medicine|2026Cited by 1
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort studyInés Suárez‐García, Ana López Lirola, Santiago Moreno et al.|AIDS Research and Therapy|2020Cited by 1